首页 › 基金 › Ghisallo Capital Management LLC › CYTK
Ghisallo Capital Management LLC 对 CYTK 的持仓历史
CYTOKINETICS INC · 医疗保健
Ghisallo Capital Management LLC 在 Q3 2026 的 13F 申报中披露持有 CYTK(CYTOKINETICS INC)170,000 股,市值约 US$11.2M,约占其申报组合的 0.26%,在其申报持仓中市值排名第 48 位。 Ghisallo Capital Management LLC 最近 10 个申报季度中有 3 个季度披露了 CYTK 持仓,最早可追溯至 Q2 2024。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Ghisallo Capital Management LLC 对 CYTK 的持仓演变
Ghisallo Capital Management LLC 于 Q2 2024 首次披露 CYTK 持仓:196,000 股(约 US$10.6M)。 该持仓在 Q2 2026 达到峰值 170,000 股,市值约 US$14.5M。 在 3 次申报中,Ghisallo Capital Management LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 170,000 股、市值约 US$11.2M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2024 | 196.00K | $10.62M | 新进 |
| Q2 2026 | 170.00K | $14.48M | 新进 |
| Q3 2026 | 170.00K | $11.20M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CYTK 与 13F 数据
CYTK(CYTOKINETICS INC)属于医疗保健行业。我们追踪的基金中还有 40 只申报持有 CYTK,申报仓位最大的包括:T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CYTK 的基金
- T. Rowe Price Investment Management, Inc. 18.72M 股 · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 4.90M 股 · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M 股 · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M 股 · $188.63M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.16M 股 · $98.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.18M 股 · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M 股 · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M 股 · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K 股 · $64.62M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K 股 · $60.88M · Q2 2026
- Melqart Asset Management (UK) Ltd 761.54K 股 · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K 股 · $49.43M · Q3 2026
更多关于 Ghisallo Capital Management LLC
常见问题
How long has Ghisallo Capital Management LLC held CYTK?
Ghisallo Capital Management LLC has disclosed CYTK holdings in 3 of the last 10 reported quarters, going back to Q2 2024.
What is Ghisallo Capital Management LLC's current position in CYTK?
As of Q3 2026, Ghisallo Capital Management LLC holds 170.00K shares of CYTK (CYTOKINETICS INC), valued at $11.20M, representing 0.26% of its reported portfolio and ranking #48.
Has Ghisallo Capital Management LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Ghisallo Capital Management LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 170.00K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.